0000950170-24-070636.txt : 20240607 0000950170-24-070636.hdr.sgml : 20240607 20240607161234 ACCESSION NUMBER: 0000950170-24-070636 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240605 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240607 DATE AS OF CHANGE: 20240607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FIBROGEN INC CENTRAL INDEX KEY: 0000921299 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36740 FILM NUMBER: 241029516 BUSINESS ADDRESS: STREET 1: 409 ILLINOIS STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-978-1200 MAIL ADDRESS: STREET 1: 409 ILLINOIS STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94158 8-K 1 fgen-20240605.htm 8-K 8-K
false000092129900009212992024-06-052024-06-05

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 05, 2024

 

 

FIBROGEN, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36740

77-0357827

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

409 Illinois Street

 

San Francisco, California

 

94158

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 415 978-1200

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.01 par value

 

FGEN

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

At the 2024 annual meeting of stockholders of FibroGen, Inc. (“FibroGen” or the “Company”) held on June 5, 2024, the stockholders voted on the five proposals listed below. The proposals are described in detail in the Company’s definitive proxy statement for the 2024 annual meeting of stockholders, filed with the Securities and Exchange Commission on April 24, 2024. The results of the matters voted upon at the meeting were:

 

(1)

 

All of the Class I nominees of the board of directors were elected to hold office until the Company’s 2027 annual meeting of stockholders. The nominees were: (i) Thane Wettig: 54,857,819 shares of Common Stock voted for, 428,789 withheld, and 17,738,031 broker non-votes; (ii) James A. Schoeneck: 53,143,223 shares of Common Stock voted for, 2,143,385 withheld, and 17,738,031 broker non-votes; and (iii) Maykin Ho, Ph.D.: 53,617,649 shares of Common Stock voted for, 1,668,959 withheld, and 17,738,031 broker non-votes.

The term of office of Class II directors Suzanne Blaug, Benjamin Cravatt, Ph.D., and Jeffrey L. Edwards continues until the Company’s 2025 annual meeting of stockholders. The term of office of Class III directors Aoife Brennan, M.B., B.Ch. and Gerald Lema, continues until the Company’s 2026 annual meeting of stockholders.

(2)

 

The stockholders approved the FibroGen, Inc. 2024 Equity Incentive Plan, attached hereto as Exhibit 10.1: 44,331,918 shares of Common Stock voted for, 10,837,159 against, and 117,531 abstaining.

(3)

 

The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the 2024 definitive proxy statement filed on April 24, 2024: 53,461,963 shares of Common Stock voted for, 1,754,540 against, and 70,105 abstaining.

(4)

 

The stockholders ratified the selection of PricewaterhouseCoopers LLP, by the Audit Committee of the FibroGen board of directors, as the independent registered public accounting firm of the Company for the year ending December 31, 2024: 72,488,928 shares of Common Stock voted for, 198,593 against, and 337,118 abstaining.

(5)

 

The stockholders approved of holding a vote, on an advisory basis, on the compensation of the Company’s named executive officers Every Year: 54,847,163 shares of Common Stock voted for Every Year, 34,601 shares of Common Stock voted for Every Two Years, 293,672 shares of Common Stock voted for Every Three Years, and 111,172 abstaining.

 

 

 

 

 

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

10.1

FibroGen, Inc. 2024 Equity Incentive Plan.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

FibroGen, Inc.

 

 

 

 

Date:

June 7, 2024

By:

/s/ Michael Lowenstein

 

 

 

Michael Lowenstein
Chief Legal Officer

 


EX-10.1 2 fgen-ex10_1.htm EX-10.1 EX-10.1

Exhibit 10.1

FibroGen, Inc.

2024 Equity Incentive Plan

Adopted by the Board of Directors: April 22, 2024

Approved by the Stockholders: June 5, 2024

 

1.
General.
(a)
Successor to and Continuation of Prior Plan.
(i)
The Plan is the successor to and continuation of the FibroGen, Inc. 2014 Equity Incentive Plan (the “Prior Plan”). From and after 12:01 a.m. Pacific time on the Effective Date, no additional stock awards will be granted under the Prior Plan. All stock awards granted under the Prior Plan remain subject to the terms of the Prior Plan. All Awards granted on or after 12:01 a.m. Pacific Time on the Effective Date will be granted under the Plan.
(ii)
Any shares that would otherwise remain available for future grants under the Prior Plan as of 12:01 a.m. Pacific Time on the Effective Date ceased to be available under the Prior Plan at such time. Instead, that number of shares of Common Stock equal to the number of shares of Common Stock of the Company then available for future grants under the Prior Plan (the “Prior Plan’s Available Reserve”) was added to the Share Reserve (as further described in Section 3(a) below) and became immediately available for grants and issuance pursuant to Stock Awards under the Plan, up to the maximum number set forth in Section 3(a) below.
(iii)
From and after 12:01 a.m. Pacific time on the Effective Date, a number of shares of Common Stock equal to the total number of shares of Common Stock subject, at such time, to outstanding stock awards granted under the Prior Plan that: (A) expire or terminate for any reason prior to exercise or settlement; (B) are forfeited or reacquired because of the failure to meet a contingency or condition required to vest such shares or are repurchased at the original issuance price; or (C) are otherwise reacquired or withheld (or not issued) to satisfy a tax withholding obligation in connection with an award or as consideration for the exercise or purchase price of an award (the “Returning Shares”) will immediately be added to the Share Reserve (as further described in Section 3(a) below) as and when such shares become Returning Shares (up to the maximum number set forth in Section 3(a)), and become available for issuance pursuant to Stock Awards granted hereunder.
(b)
Eligible Award Recipients. Employees, Directors and Consultants are eligible to receive Awards.
(c)
Available Awards. The Plan provides for the grant of the following Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards.

1

 


(d)
Purpose. The Plan, through the granting of Awards, is intended to help the Company secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate, and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.
2.
Administration.
(a)
Administration by Board. The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c).
(b)
Powers of Board. The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:
(i)
To determine: (A) who will be granted Awards; (B) when and how each Award will be granted; (C) what type of Award will be granted; (D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Award; (E) the number of shares of Common Stock subject to, or the cash value of, an Award; and (F) the Fair Market Value applicable to a Stock Award.
(ii)
To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement or in the written terms of a Performance Cash Award, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective.
(iii)
To settle all controversies regarding the Plan and Awards granted under it.
(iv)
To accelerate, in whole or in part, the time at which an Award may be exercised or vest (or at which cash or shares of Common Stock may be issued).
(v)
To suspend or terminate the Plan at any time. Except as otherwise provided in the Plan or an Award Agreement, suspension or termination of the Plan will not materially impair a Participant’s rights under his or her then-outstanding Award without his or her written consent, except as provided in subsection (viii) below.
(vi)
To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and/or to bring the Plan or Awards granted under the Plan into compliance therewith, subject to the limitations, if any, of Applicable Law. If required by Applicable Law or listing requirements, and except as provided in Section 9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A) materially increases the number of shares of Common Stock available for issuance under the Plan, (B) materially expands the class of individuals eligible to receive Awards under the Plan, (C) materially increases the benefits accruing to Participants under the Plan, (D) materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (E) materially extends the term of the Plan, or (F) materially expands the types of Awards available for issuance under the Plan. Except as otherwise provided in the

2

 


Plan or an Award Agreement, no amendment of the Plan will materially impair that Participant’s rights under an outstanding Award without his or her written consent.
(vii)
To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A) Section 422 of the Code regarding “incentive stock options” or (B) Rule 16b-3.
(viii)
To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more outstanding Awards. Except with respect to amendments that disqualify or impair the status of an Incentive Stock Option or as otherwise provided in the Plan or an Award Agreement, no amendment of an outstanding Award will materially impair that Participant’s rights under his or her outstanding Award without his or her written consent. To be clear, unless prohibited by Applicable Law, the Board may amend the terms of an Award without the affected Participant’s consent if necessary (A) to maintain the qualified status of the Award as an Incentive Stock Option, (B) to clarify the manner of exemption from, or to bring the Award into compliance with, Section 409A of the Code, or (C) to comply with other Applicable Laws or listing requirements.
(ix)
Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.
(x)
To adopt such procedures and sub-plans as are necessary or appropriate to permit or facilitate participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States or allow Awards to qualify for special tax treatment in a foreign jurisdiction; provided, that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction.
(c)
Delegation to Committee.
(i)
General. The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable). Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.
(ii)
Rule 16b-3 Compliance. The Committee may consist solely of two or more Non-Employee Directors, in accordance with Rule 16b-3.

3

 


(d)
Delegation to Other Person or Body. The Board or any Committee may delegate to one or more persons or bodies the authority to do one or more of the following to the extent permitted by Applicable Law: (i) designate recipients, other than Officers, of Options and SARs (and, to the extent permitted by Applicable Law, other Stock Awards), provided that no person or body may be delegated authority to grant an Award to himself or herself; (ii) determine the number of shares of Common Stock subject to such Stock Awards; and (iii) determine the terms of such Awards. Unless provided otherwise in the Board or Committee action regarding such delegation, each Award granted pursuant to this section will be granted on the applicable form of Award Agreement most recently approved for use by the Board or the Committee, with any modifications necessary to incorporate or reflect the terms of such Award. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to any person or body (who is not a Director or that is not comprised solely of Directors, respectively) the authority to determine the Fair Market Value.
(e)
Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons
(f)
No Repricing of Awards. Neither the Board nor any Committee will have the authority to (i) reduce the exercise or strike price of any outstanding Option or SAR or (ii) cancel any outstanding Option or SAR that has an exercise or strike price (per share) greater than the then-current Fair Market Value of the Shares in exchange for cash or other Share Awards under the Plan, unless the shareholders of the Company have approved such an action within twelve (12) months prior to such an event.
3.
Shares Subject to the Plan.
(a)
Share Reserve.
(i)
Subject to Sections 1(a)(iii), 3(b) and 9(a), the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date (the “Share Reserve”) will not exceed 11,466,792 (2,200,000 new shares of Common Stock plus the number of shares of Common Stock available for grant under the Prior Plan as of March 1, 2024), less one share of Common Stock for each share of Common Stock granted under the Prior Plan after March 1, 2024 and prior to June 5, 2024.
(ii)
For clarity, the Share Reserve is a limitation on the number of shares of Common Stock that may be issued under the Plan. As a single share may be subject to grant more than once (e.g., if a share subject to a Stock Award is forfeited, it may be made subject to grant again as provided in Section 3(b) below), the Share Reserve is not a limit on the number of Stock Awards that can be granted.
(iii)
Shares may be issued in connection with a merger or acquisition as permitted by NASDAQ Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.

4

 


(b)
Reversion of Shares to the Share Reserve. If a Stock Award or any portion of a Stock Award (i) expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or (ii) is settled in cash (i.e., the Participant receives cash rather than stock), such expiration, termination or settlement will not reduce (or otherwise offset) the number of shares of Common Stock that may be available for issuance under the Plan. If any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased will revert to and again become available for issuance under the Plan. Any shares reacquired by the Company in satisfaction of tax withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award will again become available for issuance under the Plan.
(c)
Incentive Stock Option Limit. Subject to the provisions of Section 9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 11,466,792 shares of Common Stock.
(d)
Source of Shares. The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.
4.
Eligibility.
(a)
Eligibility for Specific Stock Awards. Incentive Stock Options may be granted only to employees of the Company or a “parent corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants; provided, however, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any “parent” of the Company, as such term is defined in Rule 405 of the Securities Act, unless (i) the stock underlying such Stock Awards is treated as “service recipient stock” under Section 409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction), (ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from Section 409A of the Code, or (iii) the Company, in consultation with its legal counsel, has determined that such Stock Awards comply with the distribution requirements of Section 409A of the Code.
(b)
Ten Percent Stockholders. A Ten Percent Stockholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date of grant.
5.
Provisions relating to Options and Stock Appreciation Rights.

Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each

5

 


type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical; provided, however, that each Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions:

(a)
Term. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of ten years from the date of its grant or such shorter period specified in the Award Agreement.
(b)
Exercise Price. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Award is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A of the Code and, if applicable, Section 424(a) of the Code. Each SAR will be denominated in shares of Common Stock equivalents.
(c)
Purchase Price for Options. The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by Applicable Law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. In order to exercise an Option, the Participant must provide notice of exercise in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company. The Board will have the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment. The exercise price of an Option may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following methods of payment to the extent set forth in the Option Agreement:
(i)
by cash, check, bank draft or money order payable to the Company;
(ii)
pursuant to a “cashless exercise” program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;
(iii)
by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1) any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (2) such delivery would not violate any Applicable Law or agreement restricting the redemption of the Common

6

 


Stock, (3) any certificated shares are endorsed or accompanied by an executed assignment separate from certificate, and (4) such shares have been held by the Participant for any minimum period necessary to avoid adverse accounting treatment as a result of such delivery;
(iv)
if an Option is a Nonstatutory Stock Option, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; provided, however, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are reduced to pay the exercise price pursuant to the “net exercise,” (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or
(v)
in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Award Agreement.
(d)
Exercise and Payment of a SAR. To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date. The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such SAR.
(e)
Transferability of Options and SARs. Options and SARs may not be transferred to third party financial institutions for value. The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs will apply:
(i)
Restrictions on Transfer. An Option or SAR will not be transferable except by will or by the laws of descent and distribution (or pursuant to subsections (ii) and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. The Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration.
(ii)
Domestic Relations Orders. Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order or official marital settlement agreement or other divorce or separation instrument as permitted by

7

 


Treasury Regulations Section 1.421-1(b)(2). If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer.
(iii)
Beneficiary Designation. Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, on the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, the executor or administrator of the Participant’s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of Applicable Laws.
(f)
Vesting Generally. The total number of shares of Common Stock subject to an Option or SAR may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section 5(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised.
(g)
Termination of Continuous Service. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates (other than for Cause and other than upon the Participant’s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Award as of the date of termination of Continuous Service) within the period of time ending on the earlier of (i) the date which occurs three months following the termination of the Participant’s Continuous Service (or such longer or shorter period specified in the applicable Award Agreement) and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option or SAR will terminate.
(h)
Extension of Termination Date. Except as otherwise provided in the applicable Award Agreement, if the exercise of an Option or SAR following the termination of the Participant’s Continuous Service (other than for Cause and other than upon the Participant’s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of three months (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant’s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, and (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement. In addition, unless otherwise provided in a Participant’s Award Agreement, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant’s Continuous Service (other than for Cause) would violate the Company’s insider trading policy, then the Option or SAR will terminate

8

 


on the earlier of (i) the expiration of a period of days or months (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant’s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company’s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.
(i)
Disability of Participant. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates as a result of the Participant’s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date which occurs 12 months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option or SAR (as applicable) will terminate.
(j)
Death of Participant. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company, if (i) a Participant’s Continuous Service terminates as a result of the Participant’s death, or (ii) the Participant dies within the period (if any) specified in the Award Agreement for exercisability after the termination of the Participant’s Continuous Service for a reason other than death, then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant’s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant’s death, but only within the period ending on the earlier of (i) the date which occurs 18 months following the date of death (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of such Option or SAR as set forth in the Award Agreement. If, after the Participant’s death, the Option or SAR is not exercised within the applicable time frame, the Option or SAR will terminate.
(k)
Termination for Cause. Except as explicitly provided otherwise in a Participant’s Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant’s Continuous Service is terminated for Cause, the Option or SAR will terminate immediately upon the date on which the event giving rise to the termination for Cause first occurred, and the Participant will be prohibited from exercising his or her Option or SAR from and after the date on which the event giving rise to the termination for Cause first occurred (or, if required by law, the date of termination of Continuous Service). If a Participant’s Continuous Service is suspended pending an investigation of the existence of Cause, all of the Participant’s rights under the Option or SAR will also be suspended during the investigation period.
(l)
Non-Exempt Employees. If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six (6) months following the date of grant of the Option or SAR (although the Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt

9

 


Employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant’s retirement (as such term may be defined in the Participant’s Award Agreement in another agreement between the Participant and the Company, or, if no such definition, in accordance with the Company's then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six (6) months following the date of grant. The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee’s regular rate of pay, the provisions of this Section 5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements.
6.
Provisions of Stock Awards other than Options and SARs.
(a)
Restricted Stock Awards. Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board will deem appropriate. To the extent consistent with the Company’s bylaws, at the Board’s election, shares of Common Stock may be (x) held in book entry form subject to the Company’s instructions until any restrictions relating to the Restricted Stock Award lapse; or (y) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:
(i)
Consideration. A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under Applicable Law.
(ii)
Vesting. Shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.
(iii)
Termination of Participant’s Continuous Service. If a Participant’s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant that have not vested as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement.
(iv)
Transferability. Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement.

10

 


(b)
Restricted Stock Unit Awards. Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board will deem appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical. Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:
(i)
Consideration. At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under Applicable Law.
(ii)
Vesting. At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.
(iii)
Payment. A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.
(iv)
Additional Restrictions. At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.
(v)
Termination of Participant’s Continuous Service. Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant’s termination of Continuous Service.
(c)
Performance Awards.
(i)
Performance Stock Awards. A Performance Stock Award is a Stock Award (covering a number of shares not in excess of that set forth in Section 3(d) above) that is payable or that may be granted, may vest or may be exercised, contingent upon the attainment during a Performance Period of certain Performance Goals. A Performance Stock Award may, but need not, require the completion of a specified period of Continuous Service. The length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee in its sole discretion. In addition, to the extent permitted by Applicable Law and the applicable Award Agreement, the Board may determine that cash may be used in payment of Performance Stock Awards.

11

 


(ii)
Performance Cash Awards. A Performance Cash Award is a cash award (for a dollar value not in excess of that set forth in Section 3(d) above) that is payable contingent upon the attainment during a Performance Period of certain Performance Goals. A Performance Cash Award may also require the completion of a specified period of Continuous Service. At the time of grant of a Performance Cash Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee in its sole discretion. The Board may specify the form of payment of Performance Cash Awards, which may be cash or other property, or may provide for a Participant to have the option for his or her Performance Cash Award, or such portion thereof as the Board may specify, to be paid in whole or in part in cash or other property.
(d)
Other Stock Awards. Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof, may be granted either alone or in addition to Stock Awards provided for under Section 5 and the preceding provisions of this Section 6. Subject to the provisions of the Plan, the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.
7.
Covenants of the Company.
(a)
Availability of Shares. The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Awards.
(b)
Securities Law Compliance. The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; provided, however, that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be in violation of any applicable securities law.
(c)
No Obligation to Notify or Minimize Taxes. The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award.

12

 


8.
Miscellaneous.
(a)
Use of Proceeds from Sales of Common Stock. Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company.
(b)
Corporate Action Constituting Grant of Awards. Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.
(c)
Stockholder Rights. No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to such Award has been entered into the books and records of the Company.
(d)
No Employment or Other Service Rights. Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without Cause, (ii) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.
(e)
Change in Time Commitment. In the event a Participant’s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.
(f)
Incentive Stock Option Limitations. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options

13

 


are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with the rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).
(g)
Investment Assurances. The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Award, (i) to give written assurances satisfactory to the Company as to the Participant’s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Award for the Participant’s own account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common Stock under the Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.
(h)
Withholding Obligations. Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; provided, however, that no shares of Common Stock are withheld with a value exceeding an amount of tax calculated based on the maximum statutory tax rates in a Participant’s applicable tax jurisdiction (or such required to be withheld by law (or such lesser amount as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant, including proceeds from the sale of shares of Common Stock issued pursuant to a Stock Award; (v) a “sell to cover” arrangement; or (vi) by such other method as may be set forth in the Award Agreement.
(i)
Electronic Delivery. Any reference herein to a “written” agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company’s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).
(j)
Deferrals. To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise,

14

 


vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section 409A of the Code (to the extent applicable to a Participant). Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company. The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant’s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with Applicable Law.
(k)
Compliance with Section 409A. Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes “deferred compensation” under Section 409A of the Code is a “specified employee” for purposes of Section 409A of the Code, no distribution or payment of any amount that is due because of a “separation from service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six (6) months following the date of such Participant’s “separation from service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant’s death, unless such distribution or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six (6) month period elapses, with the balance paid thereafter on the original schedule.
(l)
Clawback/Recovery. All Awards granted under the Plan will be subject to recoupment in accordance with the Company’s current clawback policy, as it may be amended from time to time, and any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are listed or as is otherwise required by Applicable Law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of an event constituting Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for “good reason” or “constructive termination” (or similar term) under any agreement with the Company or an Affiliate.
(m)
Dividends and Dividend Equivalents. Dividends and dividend equivalents may be credited in respect of shares of Common Stock covered by a Stock Award (other than Options and SARs), as determined by the Board and contained in the applicable Award Agreement. At the sole

15

 


discretion of the Board, such dividends and dividend equivalents may be converted into additional shares of Common Stock covered by the Stock Award in such manner as determined by the Board. Any additional shares of Common Stock or cash payments covered by the Stock Award credited by reason of such dividends or dividend equivalents will be subject to all of the same terms and conditions of the underlying Award Agreement to which they relate. Notwithstanding anything to the contrary in this Plan or any Award Agreement, dividends and dividend equivalents shall not be paid in respect of shares of Common Stock covered by a Stock Award until such shares of Common Stock vest pursuant to the applicable Award Agreement.
9.
Adjustments upon Changes in Common Stock; Other Corporate Events.
(a)
Capitalization Adjustments. In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 3(c), and (iii) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board will make such adjustments, and its determination will be final, binding and conclusive.
(b)
Dissolution or Liquidation. Except as otherwise provided in the Stock Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company’s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company’s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service; provided, however, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.
(c)
Corporate Transaction. The following provisions will apply to Stock Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of a Stock Award. In the event of a Corporate Transaction, then, notwithstanding any other provision of the Plan, the Board will take one or more of the following actions with respect to Stock Awards, contingent upon the closing or completion of the Corporate Transaction:
(i)
arrange for the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company) to assume or continue the Stock Award or to substitute a similar stock award for the Stock Award (including, but not limited to, an award to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction);

16

 


(ii)
arrange for the assignment of any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to the Stock Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company);
(iii)
accelerate the vesting, in whole or in part, of the Stock Award (and, if applicable, the time at which the Stock Award may be exercised) to a date prior to the effective time of such Corporate Transaction as the Board determines (or, if the Board does not determine such a date, to the date that is five (5) days prior to the effective date of the Corporate Transaction), with such Stock Award terminating if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction;
(iv)
arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the Stock Award;
(v)
cancel or arrange for the cancellation of the Stock Award, to the extent not vested or not exercised prior to the effective time of the Corporate Transaction, in exchange for such cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; and
(vi)
cancel or arrange for the cancellation of the Stock Award, to the extent not vested or not exercised prior to the effective time of the Corporate Transaction, in exchange for a payment, in such form as may be determined by the Board, equal to the excess, if any, of (A) the value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Corporate Transaction, over (B) any exercise price payable by such holder in connection with such exercise.
(vii)
The Board need not take the same action or actions with respect to all Stock Awards or portions thereof or with respect to all Participants. The Board may take different actions with respect to the vested and unvested portions of a Stock Award.
(d)
Change in Control. A Stock Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant, but in the absence of such provision, no such acceleration will occur.
10.
Termination or Suspension of the Plan.

The Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth anniversary of the earlier of (i) the date the Plan is adopted by the Board (the “Adoption Date”), and (ii) the date the Plan is approved by the stockholders of the Company. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.

11.
Existence of the Plan.

The Plan will become effective on the Effective Date.

17

 


12.
Choice of Law.

The law of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state’s conflict of laws rules.

13.
Definitions. As used in the Plan, the following definitions will apply to the capitalized terms indicated below:
(a)
Affiliate” means, at the time of determination, any “parent” or “subsidiary” of the Company as such terms are defined in Rule 405 of the Securities Act. The Board will have the authority to determine the time or times at which “parent” or “subsidiary” status is determined within the foregoing definition.
(b)
Applicable Law” means any applicable securities, federal, state, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of any applicable self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange, or the Financial Industry Regulatory Authority).
(c)
Award” means a Stock Award or a Performance Cash Award.
(d)
Award Agreement” means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.
(e)
Board” means the Board of Directors of the Company.
(f)
Capitalization Adjustment” means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Adoption Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large non-recurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.
(g)
Capital Stockmeans each and every class of common stock of the Company, regardless of the number of votes per share.
(h)
Cause will have the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any one or more of the following events: (i) the Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude; (ii) the Participant’s attempted commission of or participation in a fraud or act of dishonesty against the Company that results in (or might have reasonably resulted in) material

18

 


harm to the business of the Company; (iii) the Participant’s intentional, material violation of any contract or agreement between the Participant and the Company or any statutory duty that the Participant owes to the Company; or (iv) the Participant’s unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) the Participant’s conduct that constitutes gross insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company. The determination that a termination of the Participant’s Continuous Service is either for Cause or without Cause will be made by the Company, in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or the Participant for any other purpose.
(i)
Change in Control” means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:
(i)
any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control will not be deemed to occur (A) on account of the acquisition of securities of the Company directly from the Company; (B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company’s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities; or (C) solely because the level of Ownership held by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control will be deemed to occur;
(ii)
there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction;
(iii)
there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than fifty percent (50%) of the combined voting

19

 


power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; or
(iv)
individuals who, on the date the Plan is adopted by the Board, are members of the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member will, for purposes of this Plan, be considered as a member of the Incumbent Board.

For purposes of determining voting power under the term Change in Control, voting power shall be calculated by assuming the conversion of all equity securities convertible (immediately or at some future time) into shares entitled to vote, but not assuming the exercise of any warrant or right to subscribe to or purchase those shares. In addition, (A) the term Change in Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B) the term Change in Control will not include a change in the voting power of any one or more stockholders as a result of the conversion of any class of the Company’s securities into another class of the Company’s securities having a different number of votes per share pursuant to the conversion provisions set forth in the Company’s Amended and Restated Certificate of Incorporation, and (C) the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant will supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition will apply. If required for compliance with Section 409A of the Code, in no event will a Change in Control be deemed to have occurred if such transaction is not also a “change in the ownership or effective control of” the Company or “a change in the ownership of a substantial portion of the assets of” the Company as determined under Treasury Regulation Section 1.409A-3(i)(5) (without regard to any alternative definition thereunder). The Board may, in its sole discretion and without a Participant’s consent, amend the definition of “Change in Control” to conform to the definition of “Change in Control” under Section 409A of the Code, and the regulations thereunder.

(j)
Code” means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.
(k)
Committee” means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).
(l)
Common Stock” means the common stock of the Company, having one vote per share.
(m)
Company” means FibroGen, Inc., a Delaware corporation.
(n)
Consultant” means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such

20

 


services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a “Consultant” for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company’s securities to such person.
(o)
Continuous Service” means that the Participant’s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant’s service with the Company or an Affiliate, will not terminate a Participant’s Continuous Service; provided, however, that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant’s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. In addition, to the extent required for exemption from or compliance with Section 409A of the Code, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of “separation from service” as defined under Treasury Regulation Section 1.409A-1(h) (without regard to any alternative definition thereunder).
(p)
Corporate Transaction” means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:
(i)
the consummation of a sale or other disposition of all or substantially all, as determined by the Board, in its sole discretion, of the consolidated assets of the Company and its Subsidiaries;
(ii)
the consummation of a sale or other disposition of at least 90% of the outstanding securities of the Company;
(iii)
the consummation of a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or
(iv)
the consummation of a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.

21

 


To the extent required for compliance with Section 409A of the Code, in no event will an event be deemed a Corporate Transaction if such transaction is not also a “change in the ownership or effective control of” the Company or “a change in the ownership of a substantial portion of the assets of” the Company as determined under Treasury Regulation Section 1.409A-3(i)(5) (without regard to any alternative definition thereunder).

(q)
Director” means a member of the Board.
(r)
Disability” means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.
(s)
Effective Date” means June 5, 2024.
(t)
Employee” means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for purposes of the Plan.
(u)
Entity” means a corporation, partnership, limited liability company or other entity.
(v)
Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
(w)
Exchange Act Person means any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities.
(x)
Fair Market Value” means, as of any date, the value of the Common Stock determined as follows:
(i)
If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.

22

 


(ii)
Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.
(iii)
In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.
(y)
Governmental Body” means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or regulatory body, or quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any Tax authority) or other body exercising similar powers or authority; or (d) self-regulatory organization (including the Nasdaq Stock Market, New York Stock Exchange, and the Financial Industry Regulatory Authority).
(z)
Incentive Stock Option” means an option granted pursuant to Section 5 of the Plan that is intended to be, and qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code.
(aa)
Non-Employee Director means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (“Regulation S-K”)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii) is otherwise considered a “non-employee director” for purposes of Rule 16b-3.
(bb)
Nonstatutory Stock Option” means any option granted pursuant to Section 5 of the Plan that does not qualify as an Incentive Stock Option.
(cc)
Officer” means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.
(dd)
Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.
(ee)
Option Agreement” means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan.
(ff)
Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.

23

 


(gg)
Other Stock Award” means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(d).
(hh)
Other Stock Award Agreement means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan.
(ii)
Own, Owned, Owner, Ownership A person or Entity will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.
(jj)
Parent” means any corporation (other than the Company) in an unbroken chain of corporations ending with the Company, if each of the corporations other than the Company owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. A corporation that attains the status of a Parent on a date after the adoption of the Plan shall be considered a Parent commencing as of such date.
(kk)
Participant” means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.
(ll)
Performance Cash Award” means an award of cash granted pursuant to the terms and conditions of Section 6(c)(ii).
(mm)
Performance Criteria” means the one or more criteria that the Committee will select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Committee: (i) earnings (including earnings per share and net earnings); (ii) earnings before interest, taxes and depreciation; (iii) earnings before interest, taxes, depreciation and amortization; (iv) earnings before interest, taxes, depreciation, amortization and legal settlements; (v) earnings before interest, taxes, depreciation, amortization, legal settlements and other income (expense); (vi) earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense) and stock-based compensation; (vii) earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense), stock-based compensation and changes in deferred revenue; (viii) total stockholder return; (ix) return on equity or average stockholder’s equity; (x) return on assets, investment, or capital employed; (xi) stock price; (xii) margin (including gross margin); (xiii) income (before or after taxes); (xiv) operating income; (xv) operating income after taxes; (xvi) pre-tax profit; (xvii) operating cash flow; (xviii) sales or revenue targets; (xix) increases in revenue or product revenue; (xx) expenses and cost reduction goals; (xxi) improvement in or attainment of working capital levels; (xxii) economic value added (or an equivalent metric); (xxiii) market share; (xxiv) cash flow; (xxv) cash flow per share; (xxvi) share price performance; (xxvii) debt reduction; (xxviii) implementation or completion of projects or processes; (xxix) employee retention; (xxx) stockholders’ equity; (xxxi) capital expenditures; (xxxii) debt levels; (xxxiii) operating profit or net operating profit; (xxxiv) workforce diversity; (xxxv) growth of net income or operating income; (xxxvi) billings; (xxxvii) bookings; (xxxviii) initiation or completion of phases of clinical

24

 


trials and/or studies by specified dates; (xxxix) patient enrollment rates, (xxxx) budget management; (xxxxi) regulatory body approval with respect to products, studies and/or trials; (xxxxii) commercial launch of products; and (xxxxiii) other measures of performance selected by the Board.
(nn)
Performance Goals” means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board (i) in the Award Agreement at the time the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects; (3) to exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of any statutory adjustments to corporate tax rates; (5) to exclude the effects of any items that are “unusual” in nature or occur “infrequently” as determined under generally accepted accounting principles; (6) to exclude the dilutive effects of acquisitions or joint ventures; (7) to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture; (8) to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9) to exclude the effects of stock based compensation and the award of bonuses under the Company’s bonus plans; (10) to exclude costs incurred in connection with potential acquisitions or divestitures that are required to expensed under generally accepted accounting principles; (11) to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles; (12) to exclude the effect of any other unusual, non-recurring gain or loss or other extraordinary item; (13) to exclude the effects of the timing of acceptance for review and/or approval of submissions to the Food and Drug Administration or any other regulatory body and (14) to exclude the effects of entering into or achieving milestones involved in licensing joint ventures. In addition, the Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Stock Award Agreement or the written terms of a Performance Cash Award.
(oo)
Performance Period” means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant’s right to and the payment of a Stock Award or a Performance Cash Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board.
(pp)
Performance Stock Award” means a Stock Award granted under the terms and conditions of Section 6(c)(i).

25

 


(qq)
Plan” means this FibroGen, Inc. 2024 Equity Incentive Plan.
(rr)
Restricted Stock Award” means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(a).
(ss)
Restricted Stock Award Agreement” means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.
(tt)
Restricted Stock Unit Award means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b).
(uu)
Restricted Stock Unit Award Agreement means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.
(vv)
Rule 16b-3” means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.
(ww)
Securities Act” means the Securities Act of 1933, as amended.
(xx)
Stock Appreciation Right” or “SAR means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5.
(yy)
Stock Appreciation Right Agreement” means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.
(zz)
Stock Award” means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right, a Performance Stock Award or any Other Stock Award.
(aaa)
Stock Award Agreement” means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan.
(bbb)
Subsidiary” means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.

26

 


(ccc)
Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than ten percent of the total combined voting power of all classes of stock of the Company or any Affiliate.

27

 


EX-101.SCH 3 fgen-20240605.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document And Entity Information
Jun. 05, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 05, 2024
Entity Registrant Name FIBROGEN, INC.
Entity Central Index Key 0000921299
Entity Emerging Growth Company false
Entity File Number 001-36740
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 77-0357827
Entity Address, Address Line One 409 Illinois Street
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94158
City Area Code 415
Local Phone Number 978-1200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol FGEN
Security Exchange Name NASDAQ
EXCEL 6 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( )"!QU@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "0@<=8I0KEZ.X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)\W**J';B^))07!!\1:2V=U@\X=DI-VW-ZV[740?P&-F?OGF M&YA61ZE#PN<4(B:RF*]&U_LL==RP U&4 %D?T*E!S[%BZ "4:87/XNH%F(<_5/[-P!=DJ.V2ZI81CJ837GR@X-O#T]OLSK5M9G M4EYC^96MI&/$#3M/?EW=W6\?6">XN*[XNN(W6\%E(Z2X?9]621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M )"!QUA(B\TA5 0 *$0 8 >&PO=V]R:W-H965T&UL MI9AO<^(V$,:_BL:]Z;0S$/\! J3 #"'A2N\NH2'MS;33%\(6H(DM^20YA&]_ M*P,V39%L(WV\<^K];,2@ZU4+WK#F"%O22STT-D8D]ZXK@XW+*'Z2J9, MP#\$=#5*Z9@MF_DCG"L[<0B7B"1.:2T$46PV=L7]S&[1M M0#[B3\ZV^N28V$=92OEB3V;1T/$L$8M9:*P$A8]7-F%Q;)6 X]M!U"GN:0-/ MCX_JT_SAX6&65+.)C+_RR&R&3L\A$5O1+#9/W^CG/*.&CH:*+DERHX&-7N0 M/VH>#7!WFM^ M0B#:!40;51D#09133&.ZKJ+ XU*2UM0$8&RK,P+KI27 M45Y'=85T7;!=HXJ'XGYB:VY+"2 ?:%))ANM,9[=/CQ_O'QID]C"Y0L"Z!5CW M$K )Y$W1&-Z^B+V13VQ7A88K>?#7#_R@WT>P>@56[Q*L^X2I-1=K\A'BS89, M9))240F'Z]756+_@ZE_"->4Q(P]9LF2JB@77\#R_V;KNMCV$Q_=*"_4N(9J) M4*I4JMPX&V1AH/")5)"Q#&86)EA&E>56HWYWCT&>^+Q_">0S?2.S"$J-KWB8 MDR))K)'L=IM>J]/M!5V,L#1Z'_7I(^$XBL"E=>-X0#[#./(HJG.'2[:]/IG% M<%5R#1.BH$MBJ*7G^[AKOT>=V#.8ZF>YK6Z9N-R""C(%2PJY#B4&6/8#'S?T M]X!%,E9K]&K)RI80X/[]'[*9UAF0 MU0+BLK6 )TM_W+Z?N8$F+U?$#WY:_DP6+,R@WBK7'C5*MCZAU2V,#%\:Y(-W MY?DDI8J\TCA#6_JQH9&MNL4N6LK+B:@2FL*;$2$KO#W"?/J:)W+^% M&RK6[.Q"MT;H8;RX&_]>Q>2>;#CMYOT+M6M$36*V B7OJ@N&K?;[X?V)D6F^ M!UU* SO:_'##*%29'0#?KZ0TQQ.[K2U^E1A]!U!+ P04 " "0@<=8GZ ; M\+$" #B# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2) M8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@ M7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY M!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"P MU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1 M%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.] MFZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PEY7 M>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[ MJ,NXZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRK MZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#Q MNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q M_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 M " "0@<=8EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_ MQ=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+ MJ1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D M5XA-/E_G;@ M2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/ M['X 4$L#!!0 ( )"!QU@ZJJ+G0 $ #P" / >&PO=V]R:V)O;VLN M>&ULC5%=:\,P#/PKQC]@20SH\0RVT+E6J:'3"T4\4V#C-E4DYPH]&09;B(S5'WC3B?PT9>H1-N6'$2&% MGN5"6&-,W&_T_$8T'D&6A^[ ](2.(2X-PW.D0XMAU]&(B^S"1I_#6(<0Y_$_ M,5)=8P5+J@X> @\Y1G"=P) :;)-6P7@H]+BB[H-5CX$E)+4* Y7L=D[E],H. MKEGD7F08YRB#N+*#\%&MA1H#V#:;7-Y-;2>C@W(-@[^&5 MC!W-CQ]W]P-02P,$% @ D(''6"0>FZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C M,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI M160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=% MKLWC":[?#'!X=/X!4$L#!!0 ( )"!QUAED'F2&0$ ,\# 3 6T-O M;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^ MDV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT M(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W" MS&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE M8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F M"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 M ( )"!QUA(B\TA5 0 *$0 8 " @0T( !X;"]W;W)K M&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$" M% ,4 " "0@<=899!YDAD! #/ P $P @ &N$@ 6T-O F;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #X$P ! end XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports fgen-20240605.htm fgen-20240605.xsd http://xbrl.sec.gov/dei/2024 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "fgen-20240605.htm": { "nsprefix": "fgen", "nsuri": "http://www.fibrogen.com/20240605", "dts": { "inline": { "local": [ "fgen-20240605.htm" ] }, "schema": { "local": [ "fgen-20240605.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_e8c413cf-8489-4f75-88f5-fb8f947cee5a", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "fgen-20240605.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e8c413cf-8489-4f75-88f5-fb8f947cee5a", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "fgen-20240605.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.fibrogen.com/20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0000950170-24-070636-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-070636-xbrl.zip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end XML 15 fgen-20240605_htm.xml IDEA: XBRL DOCUMENT 0000921299 2024-06-05 2024-06-05 false 0000921299 8-K 2024-06-05 FIBROGEN, INC. DE 001-36740 77-0357827 409 Illinois Street San Francisco CA 94158 415 978-1200 false false false false Common Stock, $0.01 par value FGEN NASDAQ false